A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer. (6th November 2014)

Record Type:
Journal Article
Title:
A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer. (6th November 2014)
Main Title:
A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer
Authors:
Cohen, Roger B
Nemunaitis, John
Gabrail, Nashat
Bazhenova, Lyudmila
Schreiber, Taylor H
Price, Melissa
Abstract:
Is Part Of:
Journal for immunotherapy of cancer. Volume 2(2014)Supplement 3
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Issue Display:
Volume 2, Issue 3 (2014)
Year:
2014
Volume:
2
Issue:
3
Issue Sort Value:
2014-0002-0003-0000
Page Start:
Page End:
Publication Date:
2014-11-06
Subjects:
Gemcitabine -- Erlotinib -- Vinorelbine -- Advanced NSCLC -- Therapeutic Cancer Vaccine
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:
http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:
10.1186/2051-1426-2-S3-P82 ↗
Languages:
English
ISSNs:
2051-1426
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
19212.xml